|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 11, 838-842, Copyright © 1997 by European Association for Cardio-thoracic Surgery
M MacKinnon, KM Kerr, G King, MM Kennedy, JS Cockburn and RR Jeffrey
OBJECTIVE: We analysed nm23, c-erbB-2 and p53 protein expression in lung
adenocarcinoma in relation to clinicopathological status and patient
survival, to elucidate any potential prognostic value. Published reports
suggest that high p53 and c-erbB-2 protein expression and loss of nm23
protein expression are associated with poor prognosis. METHODS: A total of
162 pulmonary adenocarcinomas resected between 1980 and 1991 were stained
using monoclonal antibodies to nm23 (NCL-nm23), c- erbB-2 (NCL-CB11) and
p53 (DAKO Do7). Antigen retrieval was by microwave heating and bound
antibody was visualised using standard immunohistochemical methods.
Staining was scored by two observers blinded to tumour status and patient
survival. RESULTS: Of the tumours, 101/162 (62.3%) exhibited high-level p53
expression, 30 (18.5%) showed high-level c-erbB-2 membrane staining, and 77
(47.5%) demonstrated loss of nm23 positivity. The influence of T and N
status and disease stage on postoperative survival was as expected. The
predicted effect on patient survival of nm23, c-erbB-2 or nm23 protein
expression suggested by previous studies was not verified by our work. This
was true both overall and for groups within the same T or N status or
stage. CONCLUSION: Immunohistochemical assessment of the nm23, c-erbB-2 and
p53 proteins using the above monoclonal antibodies does not have value as
an independent prognostic indicator in pulmonary adenocarcinoma.
ARTICLES
p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma
Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, UK.
This article has been cited by other articles:
![]() |
A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zafon, G. Obiols, J. CastellvI, N. Tallada, P. Galofre, E. Gemar, J. Mesa, and R. Simo nm23-H1 Immunoreactivity as a Prognostic Factor in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3975 - 3980. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |